ProfileGDS5678 / 1448675_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 77% 77% 76% 77% 78% 79% 77% 77% 76% 80% 75% 76% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.3754578
GSM967853U87-EV human glioblastoma xenograft - Control 25.2278477
GSM967854U87-EV human glioblastoma xenograft - Control 35.2347277
GSM967855U87-EV human glioblastoma xenograft - Control 45.1956276
GSM967856U87-EV human glioblastoma xenograft - Control 55.1925377
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.2481178
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.380779
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2613977
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.2623677
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.1824376
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.5745980
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.0291175
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.1216976
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.2481977